Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

References

• IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trialNeurology1993436556618469318
   PubMed Web of Science ®Google Scholar
• PatyDWLiDKInterferon beta-1b is effective in relapsing remitting multiple sclerosis. II.MRI analysis results of a multicenter, randomized, double blind, placebo controlled trial. UBC MS/MRI Study Group and The IFN beta multiple sclerosis study groupNeurology1993436626678469319
   PubMed Web of Science ®Google Scholar
• European Study Group on Interferon beta-1b in secondary progressive MSPlacebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive MSLancet1998352149114979820296
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology2006671242124916914693
   PubMed Web of Science ®Google Scholar
• KapposLFreedmanMSPolmanCHBENEFIT Study GroupEffect of early vs delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLancet2007370899717617276
   PubMed Web of Science ®Google Scholar
• PolmanCReingoldSEdanGDiagnostic criteria for Multiple Sclerosis: 2005 Revisions to the “McDonald Criteria”Ann Neurol20055884084616283615
   PubMed Web of Science ®Google Scholar
• MarkDFLuSDCreaseyAAYamamotoRLinLSSite-specific mutagenesis of the human fibroblast interferon geneProc Natl Acad Sci U S A198481566256666091102
   PubMed Web of Science ®Google Scholar
• ChiangJGloffCAYoshizawaCNWilliamsGJPharmacokinetics of recombinant interferon-beta ser in healthy volunteers and its effect on serum neopterinPharm Res1993105675728483840
   PubMed Web of Science ®Google Scholar
• WillsRJClinical pharmacokinetics of interferonsClin Pharmacokinet1990193903991702693
   PubMed Web of Science ®Google Scholar
• NoronhaAToscasAJensenMAInterferon beta decreases T cell activation and interferon gamma production in multiple sclerosisJ Neuroimmunol1993461451538360326
   PubMed Web of Science ®Google Scholar
• LuHTRileyJLBabcockGTInterferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kd DNA-binding protein, ISGF3-gammaJ Exp Med1995182151715257595221
   PubMed Web of Science ®Google Scholar
• LeppertDWaubantEBurkMROksenbertJRHauserSLInterferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosisAnn Neurol1996408468529007089
   PubMed Web of Science ®Google Scholar
• StuveODooleyNPUhmJHInterferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase- 9Ann Neurol1996408538639007090
   PubMed Web of Science ®Google Scholar
• CalabresiPATranquillLRDambrosiaJMIncreases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1bAnn Neurol1997416696749153530
   PubMed Web of Science ®Google Scholar
• RudickRARansohoffRMLeeJCIn vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosisNeurology199850129413009595977
   PubMed Web of Science ®Google Scholar
• RepMHGHintzenRQPolmanCHvan LierRAWRecombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cellsJ Neuroimmunol1996671111188765333
   PubMed Web of Science ®Google Scholar
• SegaSWraberBMesecAHorvatAIhanAIFN-beta 1a and IFN-beta 1b have different patterns of influence on cytokinesClin Neurol Neurosurg200410625525815177779
   PubMed Web of Science ®Google Scholar
• NoronhaAToscasAArnasonBGJensenMAInterferon beta augments suppressor cell function in multiple sclerosisAnn Neurol1990272072102138445
   PubMed Web of Science ®Google Scholar
• NoronhaAToscasAArnasonBGJensenMAIFN beta augments in vivo suppressor function in MSNeurology199444 Suppl 2A212
   Google Scholar
• KnoblerRLGreensteinJIJohnsonKPSystemic Recombinant Human Interferon beta treatment of relapsing remitting multiple sclerosis: pilot study analysis and six-year follow upJ Interferon Res1993133333408301153
   PubMedGoogle Scholar
• IFNB Multiple Sclerosis Study Group and the University of British Columbia. MS/MRI Analysis GroupInterferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trialNeurology199545127712857617182
   PubMed Web of Science ®Google Scholar
• ArnasonBGfor the IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis GroupHigh dose, high frequency interferon beta-1b (Betaferon/Betaseron) treatment is effective in early stage relapsing remitting multiple sclerosisNeurology200360Suppl 1A481
   Google Scholar
• FrankJARichertNBashCInterferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb− and NAb+ patientsNeurology20046271972515007120
   PubMed Web of Science ®Google Scholar
• EbersGTraboulseeALangdonDthe LTF Study GroupThe interferon beta-1b 16-year long-term follow-up study: the resultsNeurology2006supplAAN 58th MeetingSan Diego, CAA32 Po1. 079
   Google Scholar
• TrojanoMPellegriniFFuianiANew natural history of interferon beta- treated relapsing multiple sclerosisAnn Neurol20076130030617444502
   PubMed Web of Science ®Google Scholar
• De StefanoNNarayananSFrancisGSEvidence of axonal damage in the early stages of multiple sclerosis and its relevance to disabilityArch Neurol200158657011176938
   PubMed Web of Science ®Google Scholar
• KuhlmannTLingfeldGBitschASchuchardtJBruckWAcute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over timeBrain20021252202221212244078
   PubMed Web of Science ®Google Scholar
• BarnettMHPrineasJWRelapsing and remitting multiple sclerosis: pathology of the newly forming lesionAnn Neurol2004554586815048884
   PubMed Web of Science ®Google Scholar
• TrappBDPetersonJRansohoRMRudickRMorkSBoLAxonal transection in the lesions of multiple sclerosisN Engl J Med19983382782859445407
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study GroupN Engl J Med200034389890411006365
   PubMed Web of Science ®Google Scholar
• ComiGFilippiMBarkhofFEffect of early interferon treatment on conversion to definite multple sclerosis: a randomized studyLancet20013571576158211377645
   PubMed Web of Science ®Google Scholar
• PoserCMPatyDWScheinbergLNew diagnostic criteria for multiple sclerosis: guidelines for research protocolsAnn Neurol1983132272316847134
   PubMed Web of Science ®Google Scholar
• BarkhofFPolmanCHRadueEWMagnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year resultsArch Neurol2007641292129817846268
   PubMedGoogle Scholar
• PolmanCKapposLFreedmanMSBENEFIT investigatorsSubgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1bJ Neurol200825548048718004635
   PubMed Web of Science ®Google Scholar
• GoodkinDEthe North American SP MS Study GroupInterferon beta-1b in secondary progressive MS: clinical and MRI results of a 3 year randomized controlled trial [abstract]Neurology2000542352
   Web of Science ®Google Scholar
• KapposLPolmanCPozzilliCThomsonABeckmannKDahlkeFFinal analysis of the European multicenter trial of IFNbeta-1b in secondary progressive MSNeurology2001571969197511739811
   PubMed Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPIndependent Comparison of Interferon (INCOMIN) Trial Study GroupEvery-other-day interferon beta-1b vs once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicenter studyLancet2002271453146011988242
   PubMed Web of Science ®Google Scholar
• O’ConnorPArnasonBComiGInterferon beta-1b 500 mcg, interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the BEYOND. (Betaferon/Betaseron Efficacy Yielding Outcomes of New Dose) studyNeurology20087011; Late Breaking Science SupplS004
   Google Scholar
• KapposLArnasonBComiGHigh proportion of patients free from disease activity in all 3 arms of the high-dose Betaferon trialJ Neurol2008255 Suppl 23619300958
   PubMed Web of Science ®Google Scholar
• FilippiMArnasonBComiGMagnetic resonance imaging findings of a phase III trial comparing Betaferon with Copaxone treatments in relapsing-remitting multiple sclerosisJ Neurol2008255 Suppl 29
   Google Scholar
• Koch-HenriksenNSørensenPSChristensenTDanish Multiple Sclerosis GroupA randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosisNeurology2006661056106016510769
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupNeutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three yearsNeurology1996478898948857714
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group INeutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three yearsNeurology1996478898948857714
   PubMed Web of Science ®Google Scholar
• The PRISMS Study GroupInterferon neutralizing antibodies reduce clinical and magnetic resonance efficacy in multiple sclerosis patients treated with IFNβ-1a (Rebif): observations from the PRISMS 4-year extension study (abstract)Ann Neurol200048477
   Web of Science ®Google Scholar
• PolmanCHKapposLWhiteRNeutralizing antibodies during treatment of secondary progressive MS with interferon β-1bNeurology200360374312525715
   PubMed Web of Science ®Google Scholar
• KapposLClanetMSndberg-Wollheimthe European Interferon Beta-1a IM dose-Comparison Study investigatorsNeutralizing antibodies and efficacy in interferon β-1a: a 4 year controlled studyNeurology200565404716009883
   PubMed Web of Science ®Google Scholar
• RiceGPPasznerBOgerJLesauxJPatyDEbersGThe evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1bNeurology1999521277127910214759
   PubMed Web of Science ®Google Scholar
• PetkauAJWhiteRAEbersGCIFNB Multiple Sclerosis Study GroupLongitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosisMult Scler20041012613815124756
   PubMed Web of Science ®Google Scholar
• SorensenPSRossCClemmesenKMBendtzenKFrederiksenJLClinical importance of neutralising antibodies against interferon beta in patients with relapsing remitting multiple sclerosisLancet20033621184119114568740
   PubMed Web of Science ®Google Scholar
• DurelliLBarberoPBerguiMMRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosisJ Neurol Neurosurg Psychiatry20087964665117986500
   PubMed Web of Science ®Google Scholar
• MalucchiSGilliFCaldanoMA Predictive markers for response to interferon therapy in patients with multiple sclerosisNeurology2008701119112718272865
   PubMed Web of Science ®Google Scholar
• GoodinDSHurwitzBNoronhaANeutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosisJ Int Med Res20073517318717542405
   PubMed Web of Science ®Google Scholar
• BayasARieckmannPManaging the adverse effects of interferon beta therapy in multiple sclerosisDrug Saf200022149159410672896
   PubMed Web of Science ®Google Scholar
• WaltherEUHohlfeldRMultiple sclerosis: side effects of interferon beta therapy and their managementNeurology1999531622162710563602
   PubMed Web of Science ®Google Scholar
• HartungHPEarly treatment and dose optimisation BENEFIT and BEYONDJ Neurol2005252 Suppl 34450
   Google Scholar
• ComiGArnasonBCookSTolerability and adherence to Betaferon and Copaxone in a phase III clinical trialJ Neurol2008255 Suppl 2111
   Google Scholar
• AchironAFredriksonSLesson from randomised direct comparative trialsJ Neurol Sci2009277 Suppl 1S19S2419200860
   PubMed Web of Science ®Google Scholar